Comparison of treatment efficacy 1 and 2 years after thyroid remnant ablation with 1110 versus 5550 MBq of iodine-131 in patients with intermediate-risk differentiated thyroid cancer

Aghaei Atena; Ayati Narjess; Shafiei Susan; Abbasi Bita; Zakavi S. Rasoul

首页> 外文期刊>Nuclear Medicine Communications >Comparison of treatment efficacy 1 and 2 years after thyroid remnant ablation with 1110 versus 5550 MBq of iodine-131 in patients with intermediate-risk differentiated thyroid cancer

【24h】

Comparison of treatment efficacy 1 and 2 years after thyroid remnant ablation with 1110 versus 5550 MBq of iodine-131 in patients with intermediate-risk differentiated thyroid cancer

机译：治疗效能的比较1和2年后，甲状腺残余烧蚀后1110与中间风险分化甲状腺癌患者的碘-131与5550 MBQ-131

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

摘要
著录项
相似文献
相关主题

摘要

Background Radioiodine ablation may be associated with improved survival in patients with intermediate-risk follicular cell differentiated thyroid cancer (FCDTC). The aim of this study was to compare ablation efficacy of 1110 versus 5500MBq of iodine-131 (I-131) in FCDTC patients with intermediate risk.

机译：背景技术放射性碘消融可能与中性风险滤泡细胞分化甲状腺癌（FCDTC）的患者的提高存活相关。本研究的目的是将1110与5500MBQ的碘-131（I-131）的消融效能进行比较中间风险的FCDTC患者。

著录项

来源
《Nuclear Medicine Communications》 |2017年第11期|共5页
作者
Aghaei Atena; Ayati Narjess; Shafiei Susan; Abbasi Bita; Zakavi S. Rasoul;
展开▼
作者单位

Mashhad Univ Med Sci Ghaem Hosp Nucl Med Res Ctr Mashhad Iran;

Mashhad Univ Med Sci Ghaem Hosp Nucl Med Res Ctr Mashhad Iran;

Mashhad Univ Med Sci Ghaem Hosp Nucl Med Res Ctr Mashhad Iran;

Mashhad Univ Med Sci Ghaem Hosp Radiol Dept Mashhad Iran;

Mashhad Univ Med Sci Ghaem Hosp Nucl Med Res Ctr Mashhad Iran;

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类放射医学;
关键词
ablation; differentiated thyroid cancer; iodine-131; intermediate risk;

机译：消融;分化的甲状腺癌;碘-131;中间风险;

相似文献

外文文献
中文文献
专利

1. Comparison of treatment efficacy 1 and 2 years after thyroid remnant ablation with 1110 versus 5550 MBq of iodine-131 in patients with intermediate-risk differentiated thyroid cancer [J] . Aghaei Atena, Ayati Narjess, Shafiei Susan, Nuclear Medicine Communications . 2017,第11期

机译：治疗效能的比较1和2年后，甲状腺残余烧蚀后1110与中间风险分化甲状腺癌患者的碘-131与5550 MBQ-131
2. Comparison of 800 and 3700 MBq iodine-131 for the postoperative ablation of thyroid remnant in patients with low-risk differentiated thyroid cancer [J] . CaglarM., BozkurtF.M., AkcaC.K., Nuclear Medicine Communications . 2012,第3期

机译：低危分化型甲状腺癌患者术后800和3700 MBq碘-131清除甲状腺残留的比较
3. Success rate of thyroid remnant ablation for differentiated thyroid cancer based on 5550 MBq post-therapy scan [J] . I. Hommel, G.F. Pieters, A.J.M. Rijnders, Cancer control : . 2016,第4期

机译：基于5550 MBq治疗后扫描的分化型甲状腺癌甲状腺残留消融成功率
4. Clinical Engineering and Clinical Dosimetry in Patients with Differentiated Thyroid Cancer Undergoing Thyroid Remnant Ablation with Radioiodine-131 [C] . M. Medvedec, D. Dodig 12th Mediterranean conference on medical and biological engineering and computing 2010 . 2010

机译：放射性碘131消融甲状腺分化型甲状腺癌患者的临床工程和临床剂量
5. A Phase II Multi-Center Non-Randomized Parallel Group Non-Inferiority Study to Compare the Efficacy of No Radioactive Iodine Remnant Ablation to Remnant Ablation Treatment in Low- to Intermediate-Risk of Papillary Thyroid Cancer: The MOREthyroid Trial Protocol [O] . Eun Kyung Lee, You Jin Lee, Young Joo Park, 2020

机译：II期多中心非随机性平行组非劣液性研究以比较NO放射性碘残余烧蚀与低对乳头状甲状腺癌中风险的残留烧蚀处理的疗效：Morethyroid试验方案
6. A study of the time of hospital discharge of differentiated thyroid cancer patients after receiving iodine-131 for thyroid remnant ablation treatment [O] . Azizmohammadi Z., Tabei F., Shafiei B., 2013

机译：碘131消融治疗后分化型甲状腺癌患者出院时间的研究

相关主题

Comparison of treatment efficacy 1 and 2 years after thyroid remnant ablation with 1110 versus 5550 MBq of iodine-131 in patients with intermediate-risk differentiated thyroid cancer

摘要

著录项

相似文献

相关主题

期刊订阅